
Release date: 2024-08-09 17:46:36 Article From: Lucius Laos Recommended: 264
Pemigatinib is a potent and selective oral antineoplastic drug targeting the FGFR subtype, primarily for the treatment of patients with advanced cholangiocarcinoma.
The price of Pemigatinib varies depending on factors such as region, specification, and manufacturer. The most circulating version on the market is the generic version produced by Lucius Pharmaceutical Co., Ltd., with a specification of 4.5mg*14 tablets and a price of 1,400 yuan, which may change with time, market changes, and policy adjustments.
Patients should follow the doctor's instructions at the time of purchase, and the doctor will make a comprehensive assessment based on the patient's condition, individual differences, and clinical data. When using generic drugs, patients should follow their doctor's advice and proceed with treatment under the guidance of their doctor.
The original drug invests a lot of money and time in the research and development process, and the price is high. Generic drugs, on the other hand, reduce costs by replicating the active ingredient and therapeutic effect of the original drug.
Market demand and availability in different regions can also affect the price of medicines.
Drug prices are also affected by national drug regulatory policies and medical insurance policies.
Before purchasing Pemigatinib, patients should fully understand the indications, dosage, adverse reactions, and precautions of the drug, and take the drug under the guidance of a doctor.
Patients can pay attention to the dynamic changes in drug prices and choose a version with a relatively reasonable price to purchase. At the same time, you can also pay attention to the changes in the medical insurance policy, so as to know whether the drug is included in the medical insurance catalog and obtain the corresponding reimbursement support.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3502025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5512024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3362025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3512025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3262025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3922025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3252025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3002025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643